Literature DB >> 15934821

LightTyper platform for high-throughput clinical genotyping.

Gurunathan Murugesan1, Kandice Kottke-Marchant, Stephen Ellis, Ramtin Agah, Raymond Tubbs.   

Abstract

DNA sequence variations due to single nucleotide changes or polymorphisms (SNPs) have demonstrated an association with certain diseases as causative agents or surrogate biomarkers. Identification and genotyping of SNPs requires reliable and robust technologies. Multiple genotyping platforms are available to detect SNPs. Although many of these platforms meet the requirements of the research environment, technologies have also emerged for high-throughput clinical genotyping as well. The LightTyper is one such platform, providing SNP identification by employing melting curve analysis of fluorescently labeled probes. The LightTyper has been used to identify SNPs associated with myocardial infarction, developing and validating assays for approximately 100 SNPs in 30 candidate genes. The LightTyper is also amenable to the use of assays already developed for the LightCycler, which is widely used in clinical laboratories. The initial experience presented here suggests the potential use of the LightTyper for high-throughput clinical genotyping.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15934821     DOI: 10.1586/14737159.5.3.457

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  2 in total

1.  Genetic variation in small proline rich protein 2B as a predictor for asthma among children with eczema.

Authors:  Tolly G Epstein; Grace K LeMasters; David I Bernstein; Mark B Ericksen; Lisa J Martin; Patrick H Ryan; Jocelyn M Biagini Myers; Melinda S Butsch Kovacic; Mark A Lindsey; Hua He; Tiina Reponen; Manuel S Villareal; James E Lockey; Cheryl K Bernstein; Gurjit K Khurana Hershey
Journal:  Ann Allergy Asthma Immunol       Date:  2012-03       Impact factor: 6.347

2.  APOE genotyping: comparison of three methods.

Authors:  B H Rihn; S Berrahmoune; S Berahmoune; M Jouma; S Chamaa; L Marcocci; A Le Faou
Journal:  Clin Exp Med       Date:  2008-10-09       Impact factor: 3.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.